bovnews13h
Neumora Therapeutics Inc (NMRA) Stock Settles at $2.16: What’s Contributing to This Price Point?
In terms of valuation, Neumora Therapeutics Inc’s market capitalization stands at $348.98 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...
FierceBiotech9d
Neumora's dig into phase 3 depression data disappoints analysts
Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...
Levi & Korsinsky Reminds Shareholders of an Investigation into Neumora Therapeutics, Inc. (NMRA) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neumora ...
bovnews4d
Neumora Therapeutics Inc (NMRA) Posted – Profit Margin Last Year—Can It Hold Up?
Neumora Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -81.35%. The profit margin, also known as the revenue ratio or gross profit ...
Hosted on MSN22d
Neumora Therapeutics' depression drug fails to meet main goal of late-stage study
Neumora will provide additional updates on the development of the drug at an industry conference later this month. (Reporting by Sriparna Roy, Sneha S K and Kamal Choudhury in Bengaluru; Editing ...
Neumora Therapeutics Target of Unusually High Options Trading (NASDAQ:NMRA)
Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) saw some unusual options trading on Monday. Stock traders acquired 5,936 call options on the stock. This represents an increase of 45% ...
MarketWatch8d
Neumora Therapeutics’ stock craters after trial of major depressive disorder fails to meet main goals
Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.
Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals
Neumora Therapeutics ( NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a late-stage study of its experimental treatment for depression did not meet ...
Seeking Alpha21d
Neumora Therapeutics: Tanking On Disastrous MDD Data, Bounce Back Unlikely
Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 study for major depressive disorder, causing an 80% stock drop yesterday.
Reuters23d
Neumora shares slump after depression drug fails in key trial
Jan 2 (Reuters) - Neumora Therapeutics' (NMRA.O), opens new tab shares tumbled more than 80% on Thursday after its experimental depression drug failed to reduce symptoms such as sadness and ...
Benzinga.com22d
Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials
Neumora's navacaprant Phase 3 KOASTAL-1 Study failed to meet primary and key secondary endpoints for major depressive disorder. Navacaprant and placebo showed similar outcomes: -12.5 on MADRS and ...